Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Non-Current Liabilities (2016 - 2025)

Cumberland Pharmaceuticals' Other Non-Current Liabilities history spans 16 years, with the latest figure at $5.8 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 7.58% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $5.8 million, down 7.58%, while the annual FY2025 figure was $5.8 million, 7.58% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $5.8 million at Cumberland Pharmaceuticals, down from $6.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $11.3 million in Q1 2022 and bottomed at $5.8 million in Q4 2025.
  • The 5-year median for Other Non-Current Liabilities is $7.0 million (2023), against an average of $7.3 million.
  • The largest annual shift saw Other Non-Current Liabilities surged 44.56% in 2022 before it tumbled 37.38% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $7.5 million in 2021, then increased by 1.28% to $7.6 million in 2022, then decreased by 14.9% to $6.5 million in 2023, then decreased by 2.41% to $6.3 million in 2024, then fell by 7.58% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Other Non-Current Liabilities are $5.8 million (Q4 2025), $6.0 million (Q3 2025), and $6.3 million (Q2 2025).